Effects of Varenicline Tartrate on Smoking Cessation

Introduction to Smoking Hazards

Cigarette smoking poses significant health risks, including damage to the airways and alveoli in the lungs, as well as narrowing of blood vessels. It is linked to increased incidences of lung cancer, chronic obstructive pulmonary disease, and stroke. In the United States, smoking is responsible for over 480,000 fatalities annually, representing nearly 20 percent of total deaths. Many adult smokers begin this habit before the age of 21, prompting anti-smoking campaigns to target adolescents. Early cessation is crucial, leading to recent research focused on effective smoking cessation methods for young people.

Varenicline as a Treatment Option

Varenicline, a widely used medication for nicotine addiction, is the first partial agonist of nicotine receptors available. A recent study published in JAMA Pediatrics examined the efficacy of varenicline for smoking cessation in adolescents.

Study Design and Participants

The study involved 157 adolescent cigarette smokers aged 14 to 21 who were motivated to quit. Participants were divided into two groups: the experimental group, which received varenicline treatment for 12 weeks, and a control group that received a placebo. Both groups participated in weekly counseling sessions focused on smoking cessation.

Assessment of Abstinence

Abstinence from smoking was verified through urine tests conducted seven days after the treatment concluded. Participants also self-reported their smoking status weekly during the treatment and at follow-up visits. Any adverse effects related to the treatment were documented, and the time taken to achieve a complete seven-day cigarette abstinence was recorded.

Results of the Study

The findings indicated no significant difference in abstinence rates between the experimental and control groups seven days post-treatment. Additionally, short-term adverse effects were similar across both groups. However, the experimental group reached a seven-day period of abstinence more quickly on average and reported higher rates of weekly self-reported abstinence compared to the control group.

Conclusions and Future Research

This study suggests that varenicline may facilitate faster smoking cessation among young smokers with minimal short-term adverse health effects. Further research is necessary to validate these findings and explore any potential long-term health effects associated with varenicline use.

References

Gray, K. M., Baker, N. L., & McClure, E. A., et al. (2019). Efficacy and Safety of Varenicline for Adolescent Smoking Cessation: A Randomized Clinical Trial. JAMA Pediatrics. doi: 10.1001/jamapediatrics.2019.3553
Clinical trial tests varenicline to help adolescents, young adults quit smoking. (n.d.). Retrieved October 15, 2019, from https://www.eurekalert.org/pub_releases/2019-10/jn-ctt101019.php
Health Effects of Cigarette Smoking | CDC. (n.d.). Retrieved October 15, 2019, from https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/effects_cig_smoking/index.htm
Varenicline. (n.d.). Retrieved October 15, 2019, from https://www.drugbank.ca/drugs/DB01273.
Image by Lindsay Fox from Pixabay